Literature DB >> 31580450

The bulge sign - a simple physical examination for identifying progressive knee osteoarthritis: data from the Osteoarthritis Initiative.

Yuanyuan Wang1, Johanne Martel-Pelletier2, Andrew J Teichtahl1, Anita E Wluka1, Sultana Monira Hussain1, Jean-Pierre Pelletier2, Flavia M Cicuttini1.   

Abstract

OBJECTIVE: To examine whether the presence of bulge sign or patellar tap was associated with frequent knee pain, progression of radiographic OA (ROA) and total knee replacement (TKR).
METHODS: This study included 4344 Osteoarthritis Initiative participants examined at baseline for bulge sign and/or patellar tap. The clinical signs were categorized as no (none at baseline and 2 years), resolved (present at baseline only), developed (present at 2 years only) and persistent (present at both time points). Frequent knee pain and progression of ROA over 4 years and TKR over 6 years were assessed. Binary logistic regression was used to examine the associations.
RESULTS: A total of 12.7% of participants had bulge sign only, 2.0% had patellar tap only and 3.3% had both. A positive baseline bulge sign was associated with an increased risk of frequent knee pain [OR 1.31 (95% CI 1.04, 1.64), P = 0.02] and TKR [OR 1.47 (95% CI 1.06, 2.05), P = 0.02]. Developed bulge sign was associated with an increased risk of frequent knee pain [OR 1.75 (95% CI 1.34, 2.29), P < 0.001] and progressive ROA [OR 1.67 (95% CI 1.11, 2.51), P = 0.01]. Persistent bulge sign was associated with an increased risk of frequent knee pain [OR 1.60 (95% CI 1.09, 2.35), P = 0.02], progressive ROA [OR 1.84 (95% CI 1.01, 3.33), P = 0.045] and TKR [OR 2.13 (95% CI 1.23, 3.68), P = 0.007]. Patellar tap was not examined for its association with joint outcomes due to its low prevalence.
CONCLUSION: The presence of bulge sign identifies individuals at increased risk of frequent knee pain, progression of ROA and TKR. This provides clinicians with a quick, simple, inexpensive method for identifying those at higher risk of progressive knee OA who should be targeted for therapy.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bulge sign; effusion; osteoarthritis; pain; progression; total knee replacement

Year:  2020        PMID: 31580450      PMCID: PMC7244780          DOI: 10.1093/rheumatology/kez443

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  34 in total

1.  Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response.

Authors:  A Jones; M Doherty
Journal:  Ann Rheum Dis       Date:  1996-11       Impact factor: 19.103

2.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.

Authors:  N Bellamy; W W Buchanan; C H Goldsmith; J Campbell; L W Stitt
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

3.  Can structural joint damage measured with MR imaging be used to predict knee replacement in the following year?

Authors:  Frank W Roemer; C Kent Kwoh; Michael J Hannon; David J Hunter; Felix Eckstein; Zhijie Wang; Robert M Boudreau; Markus R John; Michael C Nevitt; Ali Guermazi
Journal:  Radiology       Date:  2014-10-03       Impact factor: 11.105

4.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

5.  Synovitis in knee osteoarthritis: a precursor of disease?

Authors:  I Atukorala; C K Kwoh; A Guermazi; F W Roemer; R M Boudreau; M J Hannon; D J Hunter
Journal:  Ann Rheum Dis       Date:  2014-12-08       Impact factor: 19.103

6.  Cross-sectional and Longitudinal Associations between Knee Joint Effusion Synovitis and Knee Pain in Older Adults.

Authors:  Xia Wang; Xingzhong Jin; Weiyu Han; Yuelong Cao; Andrew Halliday; Leigh Blizzard; Faming Pan; Benny Antony; Flavia Cicuttini; Graeme Jones; Changhai Ding
Journal:  J Rheumatol       Date:  2015-11-15       Impact factor: 4.666

7.  Diagnostic value of history taking and physical examination to assess effusion of the knee in traumatic knee patients in general practice.

Authors:  Marlous Kastelein; Pim A Luijsterburg; Harry P Wagemakers; Santusha C Bansraj; Marjolein Y Berger; Bart W Koes; Sita M Bierma-Zeinstra
Journal:  Arch Phys Med Rehabil       Date:  2009-01       Impact factor: 3.966

8.  Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

Authors:  Lukas Martin Wildi; Jean-Pierre Raynauld; Johanne Martel-Pelletier; André Beaulieu; Louis Bessette; Frédéric Morin; François Abram; Marc Dorais; Jean-Pierre Pelletier
Journal:  Ann Rheum Dis       Date:  2011-03-01       Impact factor: 19.103

9.  Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study.

Authors:  Jean-Pierre Pelletier; Jean-Pierre Raynauld; André D Beaulieu; Louis Bessette; Frédéric Morin; Artur J de Brum-Fernandes; Philippe Delorme; Marc Dorais; Patrice Paiement; François Abram; Johanne Martel-Pelletier
Journal:  Arthritis Res Ther       Date:  2016-11-03       Impact factor: 5.156

10.  Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study.

Authors:  Johanne Martel-Pelletier; Jean-Pierre Raynauld; François Mineau; François Abram; Patrice Paiement; Philippe Delorme; Jean-Pierre Pelletier
Journal:  Arthritis Res Ther       Date:  2017-07-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.